Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed, Gemcitabine + Bevacizumab in Elderly NSCLC
NCT00517595Phase 2Completed
- Sponsor
- Accelerated Community Oncology Research Network
- Start
- Aug 2007
- Primary completion
- Apr 2011
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed, gemcitabine and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Accelerated Community Oncology Research Network. Primary endpoint: Progression Free Survival at 15 months. Started Aug 2007; status: completed.
02
Drugs
pemetrexedgemcitabinebevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00517595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00517595.